CoChat
Sign Up
Cited by 146Atrial Fibrillation Management and OutcomesGastrointestinal Bleeding Diagnosis and TreatmentAntiplatelet Therapy and Cardiovascular Diseases

The DOI matches its Crossref record; 40 of the 42 references it cites were found in a registry or an index.

Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study

Open access
Staerk, Laila, Lip, Gregory Y H, Olesen, Jonas B, Fosbøl, Emil L, Pallisgaard, Jannik L, Bonde, Anders N, Gundlund, Anna, Lindhardt, Tommi B, Hansen, Morten L, Torp-Pedersen, Christian, Gislason, Gunnar H·2015·BMJ
DOI 10.1136/bmj.h5876PMC PMC4646074
Open this paper in CoChat — free accountOpen PDF

Abstract

STUDY QUESTION: What are the risks of all cause mortality, thromboembolism, major bleeding, and recurrent gastrointestinal bleeding associated with restarting antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation? METHODS: This Danish cohort study (1996-2012) included all patients with atrial fibrillation discharged from hospital after gastrointestinal bleeding while receiving antithrombotic treatment. Restarted treatment regimens were single or combined antithrombotic drugs with oral anticoagulation and antiplatelets. Follow-up started 90 days after discharge to avoid confounding from use of previously prescribed drugs on discharge. Risks of all cause mortality, thromboembolism, major bleeding, and recurrent gastrointestinal bleeding were estimated with competing risks models and time dependent multiple Cox regression models. STUDY ANSWER AND LIMITATIONS: 4602 patients (mean age 78 years) were included. Within two years, 39.9% (95% confidence interval 38.4% to 41.3%, n=1745) of the patients had died, 12.0% (11.0% to 13.0%, n=526) had experienced thromboembolism, 17.7% (16.5% to 18.8%, n=788) major bleeding, and 12.1% (11.1% to 13.1%, n=546) recurrent gastrointestinal bleeding. 27.1% (n=924) of patients did not resume antithrombotic treatment. Compared with non-resumption of treatment, a reduced risk of all cause mortality was found in association with restart of oral anticoagulation (hazard ratio 0.39, 95% confidence interval 0.34 to 0.46), an antiplatelet agent (0.76, 0.68 to 0.86), and oral anticoagulation plus an antiplatelet agent (0.41, 0.32 to 0.52), and a reduced risk of thromboembolism was found in association with restart of oral anticoagulation (0.41, 0.31 to 0.54), an antiplatelet agent (0.76, 0.61 to 0.95), and oral anticoagulation plus an antiplatelet agent (0.54, 0.36 to 0.82). Restarting oral anticoagulation alone was the only regimen with an increased risk of major bleeding (1.37, 1.06 to 1.77) compared with non-resumption of treatment; however, the difference in risk of recurrent gastrointestinal bleeding was not significant between patients who restarted an antithrombotic treatment regimen and those who did not resume treatment. WHAT THIS STUDY ADDS: Among patients with atrial fibrillation who experience gastrointestinal bleeding while receiving antithrombotic treatment; subsequent restart of oral anticoagulation alone was associated with better outcomes for all cause mortality and thromboembolism compared with patients who did not resume treatment. This was despite an increased longitudinal associated risk of bleeding. FUNDING, COMPETING INTERESTS, DATA SHARING: This study was supported by a grant from Boehringer-Ingelheim. Competing interests are available in the full paper on bmj.com. The authors have no additional data to share.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmj.h5876

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 42 references

2 of the 42 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Staerk, L., Lip, G. Y. H., Olesen, J. B., Fosbøl, E. L., Pallisgaard, J. L., Bonde, A. N., Gundlund, A., Lindhardt, T. B., Hansen, M. L., Torp-Pedersen, C., & Gislason, G. H.
Affiliations
  • Birmingham City Hospital (GB)
  • Herlev Hospital (DK)
  • Rigshospitalet (DK)
  • Aalborg University (DK)
  • University of Copenhagen (DK)
ORCID
Venue
BMJ
Publisher
BMJ
Published
2015-11-16
Volume
351
Pages
h5876
ISSN
1756-1833 (ISSN-L)
DOI
10.1136/bmj.h5876
PMC
PMC4646074
OpenAlex
W2175794335
Cited by
146
References
42
Citations by year
2026: 3 · 2025: 3 · 2024: 10 · 2023: 9 · 2022: 9 · 2021: 17 · 2020: 17 · 2019: 11 · 2018: 12 · 2017: 28 · 2016: 23 · 2015: 4
FWCI
16.24
Type
journal article
Language
en
Open access
Licence
Locations
  • BMJ (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion, cc-by-nc)
  • VBN Forskningsportal (Aalborg Universitet) (submittedVersion, cc-by-nc)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion, cc-by)
Funders
  • Bristol-Myers Squibb
  • Pfizer
  • AstraZeneca
  • Sanofi
  • Daiichi-Sankyo
  • Lundbeckfonden
  • Astellas Pharma
  • Region Hovedstaden
  • Novo Nordisk Fonden (NNF12OC1015957)
  • H. Lundbeck A/S
  • Janssen Pharmaceuticals
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal Bleeding Diagnosis and Treatment
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
Keywords
atrial fibrillation, gastrointestinal bleeding, antithrombotic therapy, oral anticoagulation, antiplatelet agents, recurrent gastrointestinal bleeding, stroke, thromboembolism, major bleeding, all-cause mortality, treatment discontinuation, competing risks, risk stratification, bleeding risk assessment
MeSH terms
Aged, Atrial Fibrillation, Denmark, Female, Fibrinolytic Agents, Gastrointestinal Hemorrhage, Humans, Male, Recurrence, Registries, Risk Factors, Incidence, Survival Rate, Proportional Hazards Models, Stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review